Literature DB >> 20936926

Timing of carotid surgery after acute stroke.

Mark L Keldahl1, Mark K Eskandari.   

Abstract

Carotid endarterectomy (CEA) has been proven to reduce the risk of stroke and death in both asymptomatic and symptomatic patients with carotid occlusive disease. Stroke is the third leading cause of death in the USA. Since up to one-third of stroke patients have a stroke secondary to carotid occlusive disease, it is important to offer CEA to this subgroup of patients that meet indications for surgery. Historically, literature has suggested that the optimal timing to perform CEA is approximately 6 weeks after an acute stroke. This was concluded owing to high perioperative morbidity and mortality if CEA was performed too early. However, data are increasingly showing that some patients do benefit from CEA earlier than 6 weeks after an acute stroke. This article discusses mid-20th Century literature and focuses on more recent 21st Century literature discussing the timing of CEA after acute stroke. Although there are data to support delayed CEA, it is reasonable to perform early CEA in select stroke patient populations. Candidates for early CEA should have complete or near resolution of symptoms, small infarcts on imaging and ipsilateral carotid stenosis.

Entities:  

Mesh:

Year:  2010        PMID: 20936926     DOI: 10.1586/erc.10.122

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  Early versus delayed carotid endarterectomy in symptomatic patients.

Authors:  Suman Annambhotla; Michael S Park; Mark L Keldahl; Mark D Morasch; Heron E Rodriguez; William H Pearce; Melina R Kibbe; Mark K Eskandari
Journal:  J Vasc Surg       Date:  2012-08-01       Impact factor: 4.268

2.  Safety and Efficacy of Early Carotid Endarterectomy in Patients with Symptomatic Carotid Artery Stenosis: A Meta-Analysis.

Authors:  Xiao Chen; Jing Su; Guojun Wang; Han Zhao; Shizhong Zhang; Tao Liu; Xindi Su; Ning Zhou
Journal:  Biomed Res Int       Date:  2021-01-08       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.